# reload+after+2024-01-22 22:44:28.125920
address1§6340 Sequence Drive
city§San Diego
state§CA
zip§92121
country§United States
phone§858 200 0200
website§https://www.dexcom.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
fullTimeEmployees§7500
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Kevin Ronald Sayer', 'age': 65, 'title': 'Executive Chairman, CEO & President', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 2222906, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jereme M. Sylvain', 'age': 43, 'title': 'Executive VP, CFO & Chief Accounting Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 841138, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jacob Steven Leach', 'age': 45, 'title': 'Executive VP & COO', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 994129, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Girish  Naganathan', 'age': 46, 'title': 'Executive VP & CTO', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 423920, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael Jon Brown', 'age': 53, 'title': 'Executive VP & Chief Legal Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 954455, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Shelly Ramasamy Selvaraj', 'age': 64, 'title': 'Senior VP & Chief Information Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sean  Christensen', 'title': 'Director of Corporate Affairs & Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew  Dolan', 'age': 42, 'title': 'Executive Vice President of Strategy, Corporate Development & Dexcom Labs', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sadie M. Stern', 'age': 48, 'title': 'Executive VP & Chief Human Resources Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven R. Pacelli', 'age': 51, 'title': 'Executive VP & MD of Dexcom Ventures', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 873618, 'exercisedValue': 0, 'unexercisedValue': 1865207}]
auditRisk§1
boardRisk§9
compensationRisk§2
shareHolderRightsRisk§6
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.225
priceToSalesTrailing12Months§13.90536
currency§USD
dateShortInterest§1702598400
forwardEps§1.71
pegRatio§2.51
exchange§NMS
quoteType§EQUITY
shortName§DexCom, Inc.
longName§DexCom, Inc.
firstTradeDateEpochUtc§1113485400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3ae7c86d-714e-392b-b6fd-23c89f3c2654
gmtOffSetMilliseconds§-18000000
targetHighPrice§170.0
targetLowPrice§110.0
targetMeanPrice§142.1
targetMedianPrice§145.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§20
quickRatio§2.4
earningsGrowth§0.187
grossMargins§0.63873
ebitdaMargins§0.19383
trailingPegRatio§2.5369
